Deciphering glutamine metabolism patterns for malignancy and tumor microenvironment in clear cell renal cell carcinoma
Clinical and Experimental Medicine · 2024
DOI: 10.1007/s10238-024-01390-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Medicine, 2024. Verfasst von Gengrun Wu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, 200032, People's Republic of China. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Tumor Microenvironment, Glutamine, Kidney Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: "Fuqing Scholar" Student Scientific Research Program of Shanghai Medical College, Fudan University, Shanghai Anticancer Association EYAS PROJECT, Shanghai Municipal Health Bureau Project.
Abstract (Originalsprache)
Clear cell renal cell carcinoma (ccRCC) is the most common subtype of kidney cancer characterized by metabolic reprogramming. Glutamine metabolism is pivotal in metabolic reprogramming, contributing to the significant heterogeneity observed in ccRCC. Consequently, developing prognostic markers associated with glutamine metabolism could enhance personalized treatment strategies for ccRCC patients. This study obtained RNA sequencing and clinical data from 763 ccRCC cases sourced from multiple databases. Consensus clustering of 74 glutamine metabolism related genes (GMRGs)- profiles stratified the patients into three clusters, each of which exhibited distinct prognosis, tumor microenvironment, and biological characteristics. Then, six genes (SMTNL2, MIOX, TMEM27, SLC16A12, HRH2, and SAA1) were identified by machine-learning algorithms to develop a predictive signature related to glutamine metabolism, termed as GMRScore. The GMRScore showed significant differences in clinical prognosis, expression profile of immune checkpoints, abundance of immune cells, and immunotherapy response of ccRCC patients. Besides, the nomogram incorporating the GMRScore and clinical features showed strong predictive performance in prognosis of ccRCC patients. ALDH18A1, one of the GRMGs, exhibited elevated expression level in ccRCC and was related to markedly poorer prognosis in the integrated cohort, validated by proteomic profiling of 232 ccRCC samples from Fudan University Shanghai Cancer Center (FUSCC). Conducting western blotting, CCK-8, transwell, and flow cytometry assays, we found the knockdown of ALDH18A1 in ccRCC significantly promoted apoptosis and inhibited proliferation, invasion, and epithelial-mesenchymal transition (EMT) in two human ccRCC cell lines (786-O and 769-P). In conclusion, we developed a glutamine metabolism-related prognostic signature in ccRCC, which is tightly linked to the tumor immune microenvironment and immunotherapy response, potentially facilitating precision therapy for ccRCC patients. Additionally, this study revealed the key role of ALDH18A1 in promoting ccRCC progression for the first time.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, 200032, People's Republic of China.
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, People's Republic of China.
- Shanghai Genitourinary Cancer Institute, Shanghai, 200032, People's Republic of China.
- Department of Urology, The Affiliated Taian City Central Hospital of Qingdao University, Taian, 271000, People's Republic of China.
- Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, 533000, People's Republic of China.
- Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, 200032, People's Republic of China. xwhao0407@163.com.
Förderung
- "Fuqing Scholar" Student Scientific Research Program of Shanghai Medical College, Fudan University
- Shanghai Anticancer Association EYAS PROJECT
- Shanghai Municipal Health Bureau Project
- Beijing Xisike Clinical Oncology Research Foundation
- China Anti-Cancer Association- Hengrui PARP Nicotinamide Cancer Research Fund
Zitieren
APA
Wu, G., Li, T., Chen, Y., Ye, S., Zhou, S., Tian, X., Anwaier, A., Zhu, S., Xu, W., Hao, X., Ye, D., & Zhang, H. (2024). Deciphering glutamine metabolism patterns for malignancy and tumor microenvironment in clear cell renal cell carcinoma. Clinical and Experimental Medicine. https://doi.org/10.1007/s10238-024-01390-4
Vancouver
Wu G, Li T, Chen Y, Ye S, Zhou S, Tian X, et al. Deciphering glutamine metabolism patterns for malignancy and tumor microenvironment in clear cell renal cell carcinoma. Clinical and Experimental Medicine. 2024. doi:10.1007/s10238-024-01390-4
BibTeX
@article{Wu2024,
author = {Wu, Gengrun and Li, Teng and Chen, Yuanbiao and Ye, Shiqi and Zhou, Siqi and Tian, Xi and Anwaier, Aihetaimujiang and Zhu, Shuxuan and Xu, Wenhao and Hao, Xiaohang and Ye, Dingwei and Zhang, Hailiang},
title = {Deciphering glutamine metabolism patterns for malignancy and tumor microenvironment in clear cell renal cell carcinoma},
journal = {Clinical and Experimental Medicine},
year = {2024},
doi = {10.1007/s10238-024-01390-4}
}
EUVIMED